BRIEF-Organovo Announces Fxr Program
Reuters · 03/21 12:42
Organovo Announces FXR Program
Benzinga · 03/21 12:13
Cathie Wood Bulks Up On Shopify Amid Stock's 18% Post-Earnings Drop, Sells This Major Holding Up 30% This Week
Benzinga · 02/18 14:35
SRNE, ONVO and ADX among mid-day movers
Seeking Alpha · 02/16 17:55
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 02/15 17:31
BHC, ONVO and AMAM among healthcare gainers
Seeking Alpha · 02/15 16:09
Why Tivic Health Systems Are Trading Lower By 55%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga · 02/09 17:50
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 02/09 17:31
Cardiovascular Systems, Decibel top healthcare gainers; Revelation, Veru among losers
Seeking Alpha · 02/09 15:00
Why Cardiovascular Systems Shares Are Trading Higher By 48%; Here Are 20 Stocks Moving Premarket
Benzinga · 02/09 13:54
DIS, ONVO and HIMS are among pre market gainers
Seeking Alpha · 02/09 13:26
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 02/09 13:06
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 12/21/2022 13:07
Organovo Announces Target Validation Ahead Of Schedule, Accelerating Timeline For First Crohn's Disease Drug Candidates
Benzinga · 11/15/2022 13:17
Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket
Gainers Spero Therapeutics, Inc. (NASDAQ: SPRO) rose 105.6% to $1.69 in pre-market trading. GSK and Spero Therapeutics announced exclusive license agreement for late-stage antibiotic asset, Tebipenem HBr.
Benzinga · 09/22/2022 10:34
Why Applied Optoelectronics Is Trading Higher By Around 31%; Here Are 21 Stocks Moving Premarket
Gainers Kensington Capital Acquisition Corp. IV (NYSE: AMPX) rose 159.4% to $25.94 in pre-market trading after gaining 11% on Thursday.
Benzinga · 09/16/2022 10:35
UiPath, Frontline, FLEX LNG among premarket losers' pack
Shuttle Pharmaceuticals Holdings (SHPH) -22%. UiPa...
Seekingalpha · 09/07/2022 12:29
Webull provides a variety of real-time ONVO stock news. You can receive the latest news about Organovo Holding through multiple platforms. This information may help you make smarter investment decisions.
About ONVO
Organovo Holdings, Inc. is an early stage biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). It uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted.